These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36776669)

  • 1. Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study.
    Hajjat TM; Mosha M; Whaley KG; Rosen MJ; Suppa C; Markowitz J; Dufour L; Sauer C; Shukla-Udawatta M; Boyle B; Gibson M; Shapiro J; Sams D; Sylvester F; Hunter G; Perez ME; Hyams JS
    Crohns Colitis 360; 2021 Jul; 3(3):otab039. PubMed ID: 36776669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
    Alrashed F; Abdullah I; Alfadhli A; Shehab M
    Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
    [No Abstract]   [Full Text] [Related]  

  • 4. A Single-Center Study of Long-Term Effectiveness of Vedolizumab in Anti-TNF Refractory Pediatric Inflammatory Bowel Disease.
    Patel H; Karam L; Kellermayer R
    JPGN Rep; 2023 Feb; 4(1):e276. PubMed ID: 36915867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN.
    Ledder O; Assa A; Levine A; Escher JC; de Ridder L; Ruemmele F; Shah N; Shaoul R; Wolters VM; Rodrigues A; Uhlig HH; Posovszky C; Kolho KL; Jakobsen C; Cohen S; Shouval DS; de Meij T; Martin-de-Carpi J; Richmond L; Bronsky J; Friedman M; Turner D
    J Crohns Colitis; 2017 Oct; 11(10):1230-1237. PubMed ID: 28605483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: A real-world multicenter study.
    Rébus S; Coopman S; Djeddi D; Vanrenterghem A; Dupont C; Lacotte E; Ley D
    J Pediatr Gastroenterol Nutr; 2024 Oct; ():. PubMed ID: 39415517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
    Rowland P; McNicol M; Kiel A; Maltz RM; Donegan A; Dotson JL; Michel HK; Boyle B
    J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):853-861. PubMed ID: 38270212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review.
    Fang S; Song Y; Zhang C; Wang L
    BMC Pediatr; 2022 Apr; 22(1):175. PubMed ID: 35379216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases.
    Fabiszewska S; Derda E; Szymanska E; Osiecki M; Kierkus J
    J Clin Med; 2021 Jul; 10(13):. PubMed ID: 34279480
    [No Abstract]   [Full Text] [Related]  

  • 12. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
    Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
    BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice].
    Shapina MV; Nanaeva BA
    Ter Arkh; 2020 Apr; 92(2):67-73. PubMed ID: 32598721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience.
    Ibraheim H; Samaan MA; Srinivasan A; Brain O; Digby-Bell J; Irving PM; Norman I; Jawad I; Biedermann J; Ibarra A; Kok KB; Parkes G; Rimmer J; Compot E; Parkes M; Segal J; Oppong P; Hart A; Hayee B; Powell N
    Ann Gastroenterol; 2020; 33(2):170-177. PubMed ID: 32127738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients.
    Verstockt B; Mertens E; Dreesen E; Outtier A; Noman M; Tops S; Schops G; Van Assche G; Vermeire S; Gils A; Ferrante M
    J Crohns Colitis; 2020 Mar; 14(3):332-341. PubMed ID: 31504343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
    Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
    Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Early Experience With Vedolizumab in the United States.
    Kochar B; Jiang Y; Winn A; Barnes EL; Martin CF; Long MD; Kappelman MD
    Crohns Colitis 360; 2019 Oct; 1(3):otz027. PubMed ID: 31667469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases.
    Attauabi M; Höglund C; Fassov J; Pedersen KB; Hansen HB; Wildt S; Jensen MD; Neumann A; Lind C; Jacobsen HA; Popa AM; Kjeldsen J; Pedersen N; Molazahi A; Haderslev K; Aalykke C; Knudsen T; Cebula W; Munkholm P; Bendtsen F; Seidelin JB; Burisch J
    Scand J Gastroenterol; 2021 Sep; 56(9):1040-1048. PubMed ID: 34224299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.